Note: This is the same study protocol as NCT04607746 with slight changes to how the videos will be read and a 2nd generation capsule is being studied. The purpose of this study is to evaluate the safety and effectiveness of CapsoCam® Colon (CV-3) endoscope system for the detection of colonic polyps and to show that AI-based CADe improves the polyp-detection accuracy and efficiency of capsule video readers. It will use colonoscopy results as a reference. The participant will: 1. prep for and swallow a study capsule and then 2. prep for and undergo a colonoscopy either the following day or 3-6 weeks later
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SCREENING
Masking
NONE
Enrollment
330
Participant will swallow the investigational device
SB Gastro Clinical Research
Chula Vista, California, United States
RECRUITINGGastro Care Institute
Lancaster, California, United States
RECRUITINGKnowledge Research Center
Orange, California, United States
RECRUITINGAdvanced Research Institute
St. Petersburg, Florida, United States
RECRUITINGDigestive Health Services
Downers Grove, Illinois, United States
RECRUITINGGastroenterology and Internal Medicine Specialists
Lake Barrington, Illinois, United States
RECRUITINGNorthshore Center for Gastroenterology
Libertyville, Illinois, United States
RECRUITINGSuburban Gastroenterology
Naperville, Illinois, United States
RECRUITINGSouthwest Gastroenterology
Oak Lawn, Illinois, United States
RECRUITINGGastroenterology Group of Rochester
Rochester, New York, United States
RECRUITING...and 1 more locations
Positive Percentage Agreement
• Positive Percent Agreement (PPA) of the study device with computer assisted detection (CADe) for detecting the presence in a subject of the largest polyp detected by optical colonoscopy (OC) if that polyp is ≥ 6 mm, where a match is considered to have occurred if a polyp detected by the device is assessed as having a size within plus or minus 50% of the size of the polyp detected by OC and as having a location within the same or an adjacent colon segment.
Time frame: From capsule swallow to Colonoscopy - up to 6 weeks
Negative Percentage Agreement
• Negative percent agreement (NPA) of the study device with CADe for not detecting any polyp ≥ 6 mm in a subject for whom OC did not detect any polyp ≥ 6 mm.
Time frame: From Capsule swallow to colonoscopy - Up to 6 weeks
Rebecca Petersen Sr. Director of Clinical Affairs
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.